 Home > Active Ingredient News > Blood System > Nat Med: CAR T cells targeting both CD19 and CD22 to treat relapsed or refractory B-cell malignancies: Phase I trial

Nat Med: CAR T cells targeting both CD19 and CD22 to treat relapsed or refractory B-cell malignancies: Phase I trial

 Last Update: 2021-07-30
 Source: Internet
 Author: User

Tags

target homewood al

drug medicine

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The chimeric antigen receptor-modified T cells and natural killer (NK) cells targeting CD19 (CAR19) have impressive anti-tumor effects and promote relapsed or chemotherapy-refractory (relapsed/refractory) B cell malignancies The transformation of the treatment model

Clinical factors such as pre-CAR disease burden and serum lactate dehydrogenase (LDH) are related to the response to CAR19 therapy

Some reports also indicate that effective CAR T cell response requires high target antigen expression density

CD22 is an adhesion molecule that binds to sialic acid, which is mainly limited to B cell lines and is expressed on most B line malignant tumors

Children limitations in the order of B-ALL targeted therapy of B-ALL limitations sequentially targeted therapy

Recently, in order to prevent the recurrence of CD19- or CD19lo disease, researchers tested one in a phase I clinical trial (NCT03233854) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and LBCL adults Bispecific CAR for CD19 and/or CD22 (CD19-22.

CD19-22.

The primary endpoint has been reached .

Therefore, the results of this study further imply that antigen loss is the main cause of CAR T cell resistance , highlighting the challenge that engineered multispecific CAR T cells have the same potency on different targets, and confirming that the production of cytokines is CAR An important quality indicator of T cell potency

Antigen loss is the main cause of CAR T cell resistance.

Original source:

Jay Y.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.